Advertisement
MRK vs PFE
Which Stock Would AI Choose? Merck & Co., Inc. (MRK) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- MRK has delivered stronger relative performance, gaining more than 40% year-to-date on renewed confidence in its post-Keytruda growth pipeline.
- PFE offers a significantly higher dividend yield (roughly 6%) and a much lower forward price-to-earnings (P/E) multiple than MRK.
- Both companies reported quarterly net losses tied to one-time charges, yet each reaffirmed or raised its full-year revenue outlook, reflecting resilient underlying demand.
- MRK is anchored by blockbuster oncology drug Keytruda but faces a 2028 loss of exclusivity, while PFE is navigating a nearer-term patent cliff on Eliquis and Xeljanz.
- Sentiment has favored MRK's momentum-driven story, whereas PFE's appeal is more income- and value-oriented, making the comparison a contrast between growth and yield.
Introduction
Investors weighing large-cap pharmaceutical exposure frequently find themselves comparing MRK (Merck & Co., Inc.) and PFE (Pfizer Inc.), two of the sector's most established names. While both develop, manufacture, and market medicines globally, their recent trajectories, catalysts, and market positioning differ meaningfully. This stock comparison is especially relevant for traders evaluating relative performance and for long-term investors assessing how each company is managing patent expirations, pipeline execution, and capital allocation. By examining business models, growth drivers, momentum, and risk factors side by side, this article aims to clarify how these two pharmaceutical leaders stand in the current market environment without favoring either security by wording alone.
MRK Overview and Recent Performance
Merck & Co., Inc. is a diversified pharmaceutical company whose portfolio spans oncology, vaccines, and animal health. Its flagship immunotherapy, Keytruda (pembrolizumab), remains the company's dominant revenue driver, generating more than $16 billion in the first half of 2026. In recent weeks, MRK has been one of the sector's standout performers, rallying to multi-year highs and gaining more than 40% year-to-date, a notable divergence from the broader market.
The advance has been fueled by several catalysts. Positive Phase III data from the INTerpath-001 study evaluating an individualized cancer therapy in combination with Keytruda in high-risk melanoma reinforced confidence in the oncology franchise. Newer products, including the pulmonary arterial hypertension drug Winrevair, the pneumococcal vaccine Capvaxive, and cancer treatment Welireg, have shown accelerating growth. Management has also signaled more than $70 billion of potential pipeline opportunity by the mid-2030s as it prepares for Keytruda's expected 2028 loss of exclusivity. Recent acquisitions, including Cidara Therapeutics and Terns Pharmaceuticals, added late-stage assets but also produced acquisition-related charges that pushed reported quarterly results into a loss. Despite that, MRK raised its full-year revenue guidance, and analyst consensus remains a "Buy" with an average price target above recent trading levels.
PFE Overview and Recent Performance
Pfizer Inc. is a global biopharmaceutical company with broad exposure across oncology, inflammation and immunology, vaccines, and rare diseases. Following a steep post-pandemic normalization in its COVID-19 franchise, PFE has spent recent quarters refocusing investor attention on its non-COVID portfolio and pipeline. The stock has climbed roughly 18% year-to-date and recently reached a 52-week high, aided by a broader rotation into defensive, higher-yielding healthcare names.
Pfizer's underlying business has shown resilience: it has beaten revenue expectations in nine of its last ten reports, and products such as Padcev, Lorbrena, and Nurtec ODT have delivered strong growth. Cost discipline has also been a theme, with management citing $7.2 billion removed from the cost base over three years and a further $2.5 billion productivity initiative. However, the company faces a nearer-term patent cliff, with blood thinner Eliquis and autoimmune drug Xeljanz losing U.S. exclusivity in 2026 and Ibrance and Xtandi following in 2027. A $4.3 billion non-cash impairment pushed second-quarter reported results to a loss, though adjusted earnings held steady and full-year revenue guidance was raised. Pfizer's defining feature for many investors is its dividend, recently raised to a yield near 6%—among the highest in large-cap pharma.
Trending AI Robots
For traders seeking a systematic edge in names like MRK and PFE, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, yet only a select group that best matches current market conditions earns a place in this featured section. Each bot differs in trading style, strategy, timeframe, performance statistics, and the set of tickers it trades, allowing users to review a range of approaches rather than a single method. Because the selection is refreshed to reflect prevailing market dynamics, the page serves as a useful starting point for those interested in data-driven, rules-based trading. Explore the Trending AI Robots to see which strategies are currently leading the pack.
Head-to-Head Comparison
The two companies present contrasting investment profiles. In terms of growth drivers, MRK leans heavily on oncology leadership and a pipeline designed to offset Keytruda's eventual exclusivity loss, giving it a momentum-oriented narrative. PFE is more reliant on cost-cutting, selective business development, and new oncology and obesity assets to replace revenue from drugs facing nearer-term patent expirations.
On recent momentum, MRK has clearly outperformed, with a year-to-date gain several times larger than PFE's. On valuation and income, the tables turn: PFE trades at roughly 10 times forward earnings and yields around 6%, whereas MRK's forward multiple is higher and its dividend yield is materially lower, reflecting its premium growth positioning.
Risk factors also differ. MRK's key risk is concentration—Keytruda still drives an outsized share of revenue ahead of its 2028 cliff. PFE's risks include a more compressed timeline on its patent cliff and lingering uncertainty around COVID-related revenue, which is expected to decline toward roughly $4 billion in 2026. In sector exposure terms, both are diversified large-cap pharmaceutical operators, but MRK's weighting toward oncology and vaccines contrasts with PFE's broader mix, which includes a substantial legacy cardiovascular and inflammation franchise.
Tickeron AI Verdict
Based on observable trend consistency, catalyst momentum, and relative positioning, Tickeron's AI would currently lean toward MRK. The stock has demonstrated more sustained upward momentum, clearer near-term catalysts from pipeline readouts and new product launches, and a more favorable trend structure compared with PFE. That said, PFE's high yield and low forward valuation provide a meaningful cushion that could appeal under different conditions. The AI's preference for MRK reflects a probabilistic assessment of current trend strength and catalyst flow rather than a definitive prediction, and relative positioning could shift as new earnings data and clinical milestones emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and PFE is a StrongBuy.
MRK sees its Stochastic Oscillator climbs out of oversold territory
On October 09, 2026, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 33 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 20, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 51 cases over the following month. The odds of a continued upward trend are 53%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 47 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
MRK moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.547) is normal, around the industry mean (-2.730). MRK's P/E Ratio (115.294) is considerably higher than the industry average of (21.349). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.040) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
PFE in +1.27% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 41 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 47%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 17 of 43 cases over the following month. The odds of a continued upward trend are 40%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 14 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.009) is normal, around the industry mean (-2.730). P/E Ratio (39.000) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.057) settles around the average of (0.040) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
MRK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 29 | 100 | |
SMR RATING 1..100 | 79 | 83 | |
PRICE GROWTH RATING 1..100 | 39 | 15 | |
P/E GROWTH RATING 1..100 | 1 | 3 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (89) in the Pharmaceuticals Major industry is in the same range as PFE (93). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Profit vs Risk Rating (29) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that MRK’s stock grew significantly faster than PFE’s over the last 12 months.
MRK's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as PFE (83). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
PFE's Price Growth Rating (15) in the Pharmaceuticals Major industry is in the same range as MRK (39). This means that PFE’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as PFE (3). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
| MRK | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 52% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 55% | 1 day ago 47% |
| MACD ODDS (%) | 1 day ago 53% | 1 day ago 40% |
| TrendWeek ODDS (%) | 1 day ago 49% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 42% | 1 day ago 49% |
| Advances ODDS (%) | 4 days ago 57% | 9 days ago 54% |
| Declines ODDS (%) | 1 day ago 51% | 20 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 60% | 1 day ago 52% |
| Aroon ODDS (%) | N/A | 1 day ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- MRK’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- MRK’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -0.47% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
MRK is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.28% | ||
| BMY - PFE | 57% Loosely correlated | -2.41% | ||
| AMGN - PFE | 52% Loosely correlated | -1.79% | ||
| NVS - PFE | 49% Loosely correlated | -3.30% | ||
| BIIB - PFE | 48% Loosely correlated | -1.24% | ||
| SNY - PFE | 47% Loosely correlated | -0.86% | ||
More | ||||